Barclays Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $10

Futu NewsDec 11 17:31 · Ratings

BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $3

Futu NewsDec 10 18:33 · Ratings

Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development

TipRanksDec 10 17:45 · Ratings

Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits

MT NewswiresDec 10 06:41

Express News | Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus

BreakingsDec 10 05:01

TD Cowen Maintains Fate Therapeutics(FATE.US) With Hold Rating

Futu NewsDec 6 20:33 · Ratings